We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
Read MoreHide Full Article
On Sep 22, we issued an updated research report on PetMed Express, Inc. (PETS - Free Report) . PetMed currently carries a Zacks Rank #3 (Hold).
Over the last six months, PetMed has been trading above the broader industry. Per the last trading price, the company has gained a stupendous 75.5% when compared with 27.6% growth of the broader industry.
In the fiscal first quarter, PetMed posted better-than-expected results, marking a solid start to fiscal 2018. We are encouraged by the significant increase in reorder sales and new order sales in the quarter and expect the same to continue throughout the year.
PetMed is striving to implement several strategies to revitalize its top line. These include focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items, while expanding product offerings. However, we are apprehensive about escalating advertising expenses incurred in the quarter.
The company markets its products primarily under well-known brands of medication such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel and Interceptor, among others.
On the flip side, PetMed operates in a highly competitive and fragmented pet medications market. The competitors include veterinarians, traditional retailers, other mail-order and online retailers of pet medications and other health products. Also, the acquisition of Novartis' animal health division by Eli Lilly and Company has given rise to more challenges for PetMed.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.5% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 3.5% over the last six months.
IDEXX has a long-term expected earnings growth rate of 19.8%. In the last six months, the stock has returned around 3.7%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
On Sep 22, we issued an updated research report on PetMed Express, Inc. (PETS - Free Report) . PetMed currently carries a Zacks Rank #3 (Hold).
Over the last six months, PetMed has been trading above the broader industry. Per the last trading price, the company has gained a stupendous 75.5% when compared with 27.6% growth of the broader industry.
In the fiscal first quarter, PetMed posted better-than-expected results, marking a solid start to fiscal 2018. We are encouraged by the significant increase in reorder sales and new order sales in the quarter and expect the same to continue throughout the year.
PetMed is striving to implement several strategies to revitalize its top line. These include focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items, while expanding product offerings. However, we are apprehensive about escalating advertising expenses incurred in the quarter.
The company markets its products primarily under well-known brands of medication such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel and Interceptor, among others.
On the flip side, PetMed operates in a highly competitive and fragmented pet medications market. The competitors include veterinarians, traditional retailers, other mail-order and online retailers of pet medications and other health products. Also, the acquisition of Novartis' animal health division by Eli Lilly and Company has given rise to more challenges for PetMed.
Key Picks
Some better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Amedisys, Inc. (AMED - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while IDEXX and Amedisys carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.5% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 3.5% over the last six months.
IDEXX has a long-term expected earnings growth rate of 19.8%. In the last six months, the stock has returned around 3.7%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>